

20/E.
9nd
✓ 12/14/01
Express Mail No.: BY HAND

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Richard KroczeK

Application No.: 09/509,283

Group Art Unit: 1644

Filed: August 11, 2001

Examiner: J. Roark

For: ANTI-HUMAN T-CELL COSTIMULATING
POLYPEPTIDE MONOCLONAL ANTIBODIES

Attorney Docket No.: 7853-215

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
AND/OR AMINO ACID SEQUENCE DISCLOSURES**

RECEIVED
TECH CENTER 1600/2903
01 DEC 13 AM 11:14

BOX SEQUENCE LISTING

Assistant Commissioner for Patents
Washington, DC 20231

In response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures ("Notice to Comply") mailed by the U.S. Patent and Trademark Office on October 19, 2001 in connection with the above-identified application, Applicant submits herewith a second substitute Sequence Listing in paper and computer readable form pursuant to 37 C.F.R. § 1.821 and a copy of the Notice to Comply.

The substitute paper copy and computer readable forms of the "Sequence Listing" submitted herewith correct the typographical error noted in the Notice To Comply.

I hereby state that the content of the paper and computer readable copies of the substitute Sequence Listing, submitted herewith in accordance with 37 C.F.R. §1.821, are the same. I hereby state that the submission herein does not include new matter.

Applicant further submits herewith a Petition for Extension of Time for responding to the Notice to Comply.

Respectfully submitted,

Date December 12, 2001

Laura A. Coruzzi 30,742
Laura A. Coruzzi (Reg. No.)

By:

Muna Abu-Shaar
Muna Abu-Shaar
Limited Recognition Under 37 C.F.R. § 10.9(b)
Copy of Certificate Enclosed

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures


**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATE PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Ms. Muna Abu-Sha'ar is hereby given limited recognition under 37 CFR §10.9(b) as an employee of Pennie & Edmonds, LLP to prepare and prosecute patent applications wherein the patent applicant is the client of Pennie & Edmonds, LLP, and the attorney or agent of record in the applications is a registered practitioner who is a member of Pennie & Edmonds, LLP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Ms. Muna Abu-Sha'ar ceases to lawfully reside in the United States, (ii) Ms. Muna Abu-Sha'ar's employment with Pennie & Edmonds, LLP ceases or is terminated, or (iii) Ms. Muna Abu-Sha'ar ceases to remain or reside in the United States on an H-1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: June 30, 2002



Harry Moatz, Director
Office of Enrollment and Discipline

Notice to Comply

Application No.

09/509,283

Examiner

Jessica H. Roark

Applicant(s)

KROCZEK, RICHARD

Art Unit

1644

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Newly submitted SEQ ID NO:2 does not correspond to original SEQ ID NO:2, nor does it correspond to the encoding nucleic acid sequence in SEQ ID NO:1. The error appears to be at position 151, or possibly 152 or 153, of instant SEQ ID NO:2 - a Val has been omitted versus the originally filed sequence listing.

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

#18

1600

RAW SEQUENCE LISTING

DATE: 12/13/2001

PATENT APPLICATION: US/09/509,283A

TIME: 16:30:00

Input Set : A:\7853215999.txt

Output Set: N:\CRF3\12132001\I509283A.raw

ENTERED

3 <110> APPLICANT: Kroczek, Richard
 5 <120> TITLE OF INVENTION: Anti-human T-cell costimulating monoclonal antibodies
 7 <130> FILE REFERENCE: 7853-215
 9 <140> CURRENT APPLICATION NUMBER: 09/509,283A
 10 <141> CURRENT FILING DATE: 2000-08-11
 12 <160> NUMBER OF SEQ ID NOS: 4
 14 <170> SOFTWARE: PatentIn version 3.0
 16 <210> SEQ ID NO: 1
 17 <211> LENGTH: 2641
 18 <212> TYPE: DNA
 19 <213> ORGANISM: 8F4
 21 <220> FEATURE:
 22 <221> NAME/KEY: CDS
 23 <222> LOCATION: 68..667
 25 <400> SEQUENCE: 1
 26 cgagagcctg aattcactgt cagctttgaa cactgaacgc gaggactgtt aactgtttct 60
 27 ggcaaac atg aag tca ggc ctc tgg tat ttc ttt ctc ttc tgc ttg cgc 109
 28 Met Lys Ser Gly Leu Trp Tyr Phe Phe Leu Phe Cys Leu Arg
 29 1 5 10
 30 att aaa gtt tta aca gga gaa atc aat ggt tct gcc aat tat gag atg 157
 31 Ile Lys Val Leu Thr Gly Glu Ile Asn Gly Ser Ala Asn Tyr Glu Met
 32 15 20 25 30
 33 ttt ata ttt cac aac gga ggt gta caa att tta tgc aaa tat cct gac 205
 34 Phe Ile Phe His Asn Gly Gly Val Gln Ile Leu Cys Lys Tyr Pro Asp
 35 35 40 45
 36 att gtc cag caa ttt aaa atg cag ttg ctg aaa ggg ggg caa ata ctc 253
 37 Ile Val Gln Gln Phe Lys Met Gln Leu Leu Lys Gly Gly Gln Ile Leu
 38 50 55 60
 39 tgc gat ctc act aag aca aaa gga agt gga aac aca gtg tcc att aag 301
 40 Cys Asp Leu Thr Lys Thr Lys Gly Ser Gly Asn Thr Val Ser Ile Lys
 41 65 70 75
 42 agt ctg aaa ttc tgc cat tct cag tta tcc aac aac agt gtc tct ttt 349
 43 Ser Leu Lys Phe Cys His Ser Gln Leu Ser Asn Asn Ser Val Ser Phe
 44 80 85 90
 45 ttt cta tac aac ttg gac cat tct cat gcc aac tat tac ttc tgc aac 397
 46 Phe Leu Tyr Asn Leu Asp His Ser His Ala Asn Tyr Tyr Phe Cys Asn
 47 95 100 105 110
 48 cta tca att ttt gat cct cct cct ttt aaa gta act ctt aca gga gga 445
 49 Leu Ser Ile Phe Asp Pro Pro Pro Phe Lys Val Thr Leu Thr Gly Gly
 50 115 120 125
 51 tat ttg cat att tat gaa tca caa ctt tgt tgc cag ctg aag ttc tgg 493
 52 Tyr Leu His Ile Tyr Glu Ser Gln Leu Cys Cys Gln Leu Lys Phe Trp
 53 130 135 140
 54 tta ccc ata gga tgt gca gcc ttt gtt gta gtc tgc att ttg gga tgc 541
 55 Leu Pro Ile Gly Cys Ala Ala Phe Val Val Val Cys Ile Leu Gly Cys
 56 145 150 155
 57 ata ctt att tgt tgg ctt aca aaa aag aag tat tca tcc agt gtg cac 589

RAW SEQUENCE LISTING

DATE: 12/13/2001

PATENT APPLICATION: US/09/509,283A

TIME: 16:30:00

Input Set : A:\7853215999.txt

Output Set: N:\CRF3\12132001\I509283A.raw

```

58 Ile Leu Ile Cys Trp Leu Thr Lys Lys Lys Tyr Ser Ser Ser Val His
59   160                               165                               170
60 gac cct aac ggt gaa tac atg ttc atg aga gca gtg aac aca gcc aaa      637
61 Asp Pro Asn Gly Glu Tyr Met Phe Met Arg Ala Val Asn Thr Ala Lys
62 175                               180                               185                               190
63 aaa tct aga ctc aca gat gtg acc cta taa tatggaactc tggcaccag      687
64 Lys Ser Arg Leu Thr Asp Val Thr Leu
65                               195
66 gcatgaagca cgttggccag ttttcctcaa cttgaagtgc aagattctct tatttcctggg      747
67 accacggaga gtctgactta actacataca tcttctgtct gtgttttggt caatctggaa      807
68 gaatgactgt atcagtcagt ggggatttta acagactgcc ttggtactgc cgagtcctct      867
69 caaaacaaac accctcttgc aaccagcttt ggagaaagcc cagctcctgt gtgctcactg      927
70 ggagtggagt ccctgtctcc acatctgtct ctagcagtgc atcagccagt aaaacaaaca      987
71 catttacaag aaaaatggtt taaagatgcc aggggtactg aatctgcaaa gcaaatgagc    1047
72 agccaaggac cagcatctgt ccgcatttca ctatcatact acctcttctt tctgtaggga    1107
73 tgagaattcc tcttttaatc agtcaaggga gatgcttcaa agctggagct attttatttc    1167
74 tgagatgttg atgtgaactg tacattagta catactcagt actctccttc aattgctgaa    1227
75 cccagattga ccattttacc aagactttag atgctttctt gtgccctcaa ttttcttttt    1287
76 aaaaatactt ctacatgact gcttgacagc ccaacagcca ctctcaatag agagctatgt    1347
77 cttacattct ttcctctgct gctcaatagt tttatatatc tatgcataca tatatacaca    1407
78 catatgtata taaaattcat aatgaatata tttgcctata ttctccctac aagaatattt    1467
79 ttgctccaga aagacatgtt cttttctcaa attcagttaa aatggtttac tttgttcaag    1527
80 ttagtggtag gaaacattgc ccggaattga aagcaaattt attttattat cctattttct    1587
81 accattatct atgttttcat ggtgctatta attacaagtt tagttctttt tgtagatcat    1647
82 attaaaattg caaacaaaat catctttaat gggccagcat tctcatgggg tagagcagaa    1707
83 tattcattta gcctgaaagc tgcagttact ataggttgct gtcagactat acccatgggtg    1767
84 cctctgggct tgacagggtc aaatgggtccc catcagcctg gacgagccct ccagacctgg    1827
85 gtggaattcc agggttgaga gactcccctg agccagaggg cactaggtat tcttgctccc    1887
86 agaggctgaa gtcaccctgg gaatcacagt ggtctacctg cattcataat tccaggatct    1947
87 gtgaagagca catatgtgtc agggcacaaat tccctctcat aaaaaccaca cagcctggaa    2007
88 attggccctg gcccttcaag atagccttct ttagaatatg atttggctag aaagattctt    2067
89 aaatatgttg aatatgatta ttcttagctg gaatttttct tctacttctt gtctgcactg    2127
90 ccaaggcttc tgaagcagcc aatgtcgatg caacaacatt tgtaacttta ggtaaaactgg    2187
91 gattatgttg tagtttaaca ttttgtaact gtgtgcttat agtttacaag tgagaccgga    2247
92 tatgtcatta tgcatactta tattatctta agcatgtgta atgctggatg tgtacagtac    2307
93 agtactgaac ttgtaatttg aatctagtat ggtgttctgt tttcagctga cttggacaac    2367
94 ctgactggct ttgcacaggt gttccctgag ttgtttgcag gtttctgtgt gtgggggtggg    2427
95 gtatggggag gagaaccttc atggtggccc acctggcctg gttgtccaag ctgtgcctcg    2487
96 acacatcttc atccccagca tgggacacct caagatgaat aataattcac aaaatttctg    2547
97 tgaaatcaaa tccagtttta agaggagcca cttatcaaag agattttaac agtagtaaga    2607
98 aggcaaagaa taaacatttg atattcagca actg      2641
100 <210> SEQ ID NO: 2
101 <211> LENGTH: 199
102 <212> TYPE: PRT
103 <213> ORGANISM: 8F4
105 <400> SEQUENCE: 2
106 Met Lys Ser Gly Leu Trp Tyr Phe Phe Leu Phe Cys Leu Arg Ile Lys
107 1                               5                               10                               15
109 Val Leu Thr Gly Glu Ile Asn Gly Ser Ala Asn Tyr Glu Met Phe Ile

```

RAW SEQUENCE LISTING

DATE: 12/13/2001

PATENT APPLICATION: US/09/509,283A

TIME: 16:30:00

Input Set : A:\7853215999.txt

Output Set: N:\CRF3\12132001\I509283A.raw

```

110          20          25          30
112 Phe His Asn Gly Gly Val Gln Ile Leu Cys Lys Tyr Pro Asp Ile Val
113          35          40          45
115 Gln Gln Phe Lys Met Gln Leu Leu Lys Gly Gly Gln Ile Leu Cys Asp
116          50          55          60
118 Leu Thr Lys Thr Lys Gly Ser Gly Asn Thr Val Ser Ile Lys Ser Leu
119 65          70          75          80
121 Lys Phe Cys His Ser Gln Leu Ser Asn Asn Ser Val Ser Phe Phe Leu
122          85          90          95
124 Tyr Asn Leu Asp His Ser His Ala Asn Tyr Tyr Phe Cys Asn Leu Ser
125          100         105         110
127 Ile Phe Asp Pro Pro Pro Phe Lys Val Thr Leu Thr Gly Gly Tyr Leu
128          115         120         125
130 His Ile Tyr Glu Ser Gln Leu Cys Cys Gln Leu Lys Phe Trp Leu Pro
131          130         135         140
133 Ile Gly Cys Ala Ala Phe Val Val Val Cys Ile Leu Gly Cys Ile Leu
134 145          150          155          160
136 Ile Cys Trp Leu Thr Lys Lys Lys Tyr Ser Ser Ser Val His Asp Pro
137          165         170         175
139 Asn Gly Glu Tyr Met Phe Met Arg Ala Val Asn Thr Ala Lys Lys Ser
140          180         185         190
142 Arg Leu Thr Asp Val Thr Leu
143          195
145 <210> SEQ ID NO: 3
146 <211> LENGTH: 17
147 <212> TYPE: PRT
148 <213> ORGANISM: 8F4
150 <400> SEQUENCE: 3
151 Met Gly Asn Cys Thr Ser Ala Cys Asn Gly Ala Tyr Gly Thr Asn Ala
152 1          5          10          15
153 Cys
155 <210> SEQ ID NO: 4
156 <211> LENGTH: 17
157 <212> TYPE: PRT
158 <213> ORGANISM: 8F4
160 <400> SEQUENCE: 4
162 Met Gly Asn Tyr Thr Asp Ala Cys Asn Gly Ala Tyr Gly Thr Asn Ala
163 1          5          10          15
164 Cys

```

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/509,283A

DATE: 12/13/2001

TIME: 16:30:01

Input Set : A:\7853215999.txt

Output Set: N:\CRF3\12132001\I509283A.raw